Adrienne Gropper Waks, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 41 | 2025 | 21163 | 2.350 |
Why?
|
Receptor, erbB-2 | 21 | 2025 | 2588 | 2.160 |
Why?
|
Neoadjuvant Therapy | 12 | 2024 | 2909 | 0.940 |
Why?
|
Receptors, Progesterone | 7 | 2025 | 1145 | 0.930 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 19 | 2024 | 11854 | 0.710 |
Why?
|
Receptors, Estrogen | 9 | 2025 | 2247 | 0.610 |
Why?
|
Paclitaxel | 6 | 2024 | 1736 | 0.550 |
Why?
|
Chemotherapy, Adjuvant | 7 | 2024 | 3553 | 0.520 |
Why?
|
Drug Resistance, Neoplasm | 5 | 2024 | 5335 | 0.510 |
Why?
|
Pneumocystis carinii | 1 | 2015 | 72 | 0.480 |
Why?
|
Estrogen Receptor alpha | 1 | 2019 | 580 | 0.480 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 2 | 2021 | 1105 | 0.460 |
Why?
|
Pneumonia, Pneumocystis | 1 | 2015 | 242 | 0.450 |
Why?
|
Protein Kinase Inhibitors | 4 | 2024 | 5707 | 0.420 |
Why?
|
Sentinel Lymph Node Biopsy | 4 | 2025 | 740 | 0.420 |
Why?
|
Opportunistic Infections | 1 | 2015 | 375 | 0.410 |
Why?
|
Cervix Uteri | 1 | 2015 | 577 | 0.380 |
Why?
|
Carcinoma, Lobular | 1 | 2015 | 480 | 0.370 |
Why?
|
Infertility | 1 | 2016 | 655 | 0.320 |
Why?
|
Antineoplastic Agents | 4 | 2020 | 13696 | 0.300 |
Why?
|
Neoplasm Staging | 8 | 2024 | 11254 | 0.280 |
Why?
|
Tumor Microenvironment | 2 | 2021 | 3940 | 0.270 |
Why?
|
Female | 44 | 2025 | 397050 | 0.270 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2015 | 2044 | 0.210 |
Why?
|
Ovarian Neoplasms | 1 | 2020 | 4908 | 0.210 |
Why?
|
Taxoids | 2 | 2023 | 668 | 0.200 |
Why?
|
Prospective Studies | 9 | 2024 | 54921 | 0.190 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2014 | 259 | 0.190 |
Why?
|
Suburban Population | 1 | 2011 | 54 | 0.190 |
Why?
|
Humans | 45 | 2025 | 768298 | 0.190 |
Why?
|
Genomics | 5 | 2024 | 5916 | 0.190 |
Why?
|
Fibroblast Growth Factor 3 | 1 | 2020 | 17 | 0.180 |
Why?
|
Lymph Node Excision | 2 | 2023 | 1274 | 0.180 |
Why?
|
Drug Synergism | 1 | 2024 | 1760 | 0.170 |
Why?
|
Filgrastim | 1 | 2020 | 131 | 0.170 |
Why?
|
Schistosoma haematobium | 1 | 2009 | 13 | 0.170 |
Why?
|
Schistosomiasis haematobia | 1 | 2009 | 15 | 0.170 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2020 | 259 | 0.160 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2020 | 213 | 0.160 |
Why?
|
Prognosis | 7 | 2025 | 30020 | 0.160 |
Why?
|
Schistosomiasis mansoni | 1 | 2009 | 94 | 0.160 |
Why?
|
Schistosoma mansoni | 1 | 2009 | 156 | 0.150 |
Why?
|
Platinum | 1 | 2020 | 222 | 0.150 |
Why?
|
Genes, erbB-2 | 1 | 2019 | 162 | 0.150 |
Why?
|
Germ Cells | 1 | 2022 | 643 | 0.150 |
Why?
|
Aromatase Inhibitors | 2 | 2019 | 519 | 0.150 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2022 | 906 | 0.150 |
Why?
|
Carcinoma, Basal Cell | 1 | 2012 | 562 | 0.130 |
Why?
|
RNA | 2 | 2024 | 2726 | 0.130 |
Why?
|
Middle Aged | 17 | 2025 | 223463 | 0.130 |
Why?
|
Ligands | 1 | 2022 | 3283 | 0.120 |
Why?
|
Pregnancy | 2 | 2016 | 30198 | 0.120 |
Why?
|
BRCA2 Protein | 1 | 2020 | 802 | 0.120 |
Why?
|
Piperazines | 3 | 2020 | 2552 | 0.120 |
Why?
|
Polyethylene Glycols | 1 | 2020 | 1195 | 0.120 |
Why?
|
Cyclophosphamide | 1 | 2020 | 2226 | 0.110 |
Why?
|
Gene Amplification | 1 | 2019 | 1090 | 0.110 |
Why?
|
Anthracyclines | 1 | 2015 | 286 | 0.110 |
Why?
|
Pyridines | 3 | 2020 | 2889 | 0.110 |
Why?
|
Doxorubicin | 1 | 2020 | 2229 | 0.110 |
Why?
|
Survivors | 2 | 2016 | 2382 | 0.110 |
Why?
|
BRCA1 Protein | 1 | 2020 | 1158 | 0.110 |
Why?
|
Molecular Targeted Therapy | 1 | 2024 | 2830 | 0.100 |
Why?
|
Hepatitis C | 1 | 2023 | 1593 | 0.100 |
Why?
|
Amenorrhea | 1 | 2016 | 484 | 0.100 |
Why?
|
Patient Selection | 1 | 2024 | 4265 | 0.100 |
Why?
|
DNA, Neoplasm | 1 | 2017 | 1748 | 0.100 |
Why?
|
Adult | 12 | 2024 | 223622 | 0.090 |
Why?
|
Axilla | 2 | 2024 | 628 | 0.090 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2024 | 9433 | 0.090 |
Why?
|
Neoplasm Metastasis | 2 | 2020 | 4921 | 0.090 |
Why?
|
Gonadotropin-Releasing Hormone | 1 | 2016 | 1149 | 0.090 |
Why?
|
Breast Neoplasms, Male | 1 | 2011 | 212 | 0.080 |
Why?
|
Zambia | 2 | 2011 | 273 | 0.080 |
Why?
|
Artificial Intelligence | 1 | 2024 | 2661 | 0.080 |
Why?
|
Tumor Burden | 1 | 2015 | 1913 | 0.080 |
Why?
|
Aged | 9 | 2024 | 171544 | 0.080 |
Why?
|
Survival Rate | 2 | 2025 | 12870 | 0.080 |
Why?
|
Immunotherapy | 1 | 2024 | 4740 | 0.080 |
Why?
|
Cell Cycle Proteins | 1 | 2020 | 3457 | 0.080 |
Why?
|
Mutation | 3 | 2023 | 30230 | 0.070 |
Why?
|
Head and Neck Neoplasms | 1 | 2012 | 2923 | 0.070 |
Why?
|
Combined Modality Therapy | 1 | 2019 | 8562 | 0.070 |
Why?
|
Communication | 1 | 2011 | 3912 | 0.070 |
Why?
|
Adrenal Cortex Hormones | 1 | 2015 | 1890 | 0.070 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2011 | 4047 | 0.070 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2019 | 4647 | 0.060 |
Why?
|
Disease-Free Survival | 3 | 2024 | 6856 | 0.060 |
Why?
|
Disease Management | 1 | 2015 | 2536 | 0.060 |
Why?
|
Methylene Blue | 1 | 2014 | 156 | 0.060 |
Why?
|
Skin Neoplasms | 1 | 2012 | 5857 | 0.050 |
Why?
|
Treatment Outcome | 5 | 2023 | 65365 | 0.050 |
Why?
|
Coloring Agents | 1 | 2014 | 563 | 0.050 |
Why?
|
Schools | 2 | 2011 | 1496 | 0.050 |
Why?
|
Premedication | 1 | 2021 | 246 | 0.050 |
Why?
|
Comorbidity | 1 | 2015 | 10588 | 0.040 |
Why?
|
Parotid Neoplasms | 1 | 2012 | 158 | 0.040 |
Why?
|
Quality of Life | 1 | 2022 | 13499 | 0.040 |
Why?
|
Parasite Egg Count | 1 | 2009 | 29 | 0.040 |
Why?
|
Retinoblastoma Binding Proteins | 1 | 2020 | 102 | 0.040 |
Why?
|
Receptors, Steroid | 1 | 2020 | 156 | 0.040 |
Why?
|
Mastectomy, Segmental | 1 | 2024 | 961 | 0.040 |
Why?
|
Comprehension | 1 | 2024 | 641 | 0.040 |
Why?
|
Cell Line, Tumor | 3 | 2020 | 17132 | 0.040 |
Why?
|
Health Literacy | 1 | 2024 | 468 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2015 | 10377 | 0.040 |
Why?
|
Follow-Up Studies | 4 | 2024 | 39405 | 0.040 |
Why?
|
Urine | 1 | 2009 | 363 | 0.040 |
Why?
|
Estrogens | 1 | 2024 | 1534 | 0.040 |
Why?
|
Incidence | 1 | 2015 | 21544 | 0.030 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2018 | 354 | 0.030 |
Why?
|
Postmenopause | 1 | 2024 | 2518 | 0.030 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2018 | 566 | 0.030 |
Why?
|
HIV Infections | 1 | 2011 | 17575 | 0.030 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2024 | 2884 | 0.030 |
Why?
|
Patient Education as Topic | 1 | 2024 | 2337 | 0.030 |
Why?
|
Lymphatic Metastasis | 1 | 2012 | 2924 | 0.030 |
Why?
|
Tamoxifen | 1 | 2018 | 968 | 0.030 |
Why?
|
Breast | 1 | 2023 | 1975 | 0.030 |
Why?
|
HIV | 1 | 2011 | 1596 | 0.030 |
Why?
|
Age Distribution | 1 | 2009 | 2877 | 0.030 |
Why?
|
Male | 7 | 2023 | 364870 | 0.030 |
Why?
|
Gene Dosage | 1 | 2017 | 1221 | 0.030 |
Why?
|
Risk Factors | 2 | 2015 | 74954 | 0.030 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 1765 | 0.020 |
Why?
|
Estradiol | 1 | 2019 | 1952 | 0.020 |
Why?
|
Preoperative Period | 1 | 2014 | 563 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2020 | 3616 | 0.020 |
Why?
|
Urban Population | 1 | 2009 | 2045 | 0.020 |
Why?
|
Lymph Nodes | 1 | 2023 | 3471 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2020 | 2461 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2019 | 3631 | 0.020 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2020 | 1902 | 0.020 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2018 | 1536 | 0.020 |
Why?
|
Antigens, Neoplasm | 1 | 2017 | 1999 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2018 | 4286 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2017 | 4120 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2024 | 12801 | 0.020 |
Why?
|
Caregivers | 1 | 2011 | 2303 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2019 | 5311 | 0.020 |
Why?
|
Biopsy | 1 | 2020 | 6808 | 0.020 |
Why?
|
Child, Preschool | 2 | 2011 | 42654 | 0.020 |
Why?
|
Mastectomy | 1 | 2014 | 1851 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2009 | 7861 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2024 | 20224 | 0.020 |
Why?
|
Sex Factors | 1 | 2009 | 10656 | 0.020 |
Why?
|
Up-Regulation | 1 | 2014 | 4137 | 0.020 |
Why?
|
Cell Line | 1 | 2018 | 15593 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2020 | 8628 | 0.010 |
Why?
|
Software | 1 | 2017 | 4452 | 0.010 |
Why?
|
Prevalence | 1 | 2009 | 15868 | 0.010 |
Why?
|
Child | 2 | 2011 | 80894 | 0.010 |
Why?
|
Adolescent | 2 | 2011 | 89182 | 0.010 |
Why?
|
Signal Transduction | 1 | 2024 | 23629 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2011 | 26373 | 0.010 |
Why?
|
Patient Satisfaction | 1 | 2011 | 3485 | 0.010 |
Why?
|
Physician-Patient Relations | 1 | 2011 | 3267 | 0.010 |
Why?
|
Pilot Projects | 1 | 2011 | 8730 | 0.010 |
Why?
|
Anxiety | 1 | 2011 | 4675 | 0.010 |
Why?
|
Prostatic Neoplasms | 1 | 2017 | 11220 | 0.010 |
Why?
|
Retrospective Studies | 1 | 2023 | 81768 | 0.010 |
Why?
|
Young Adult | 1 | 2020 | 60048 | 0.010 |
Why?
|
Animals | 1 | 2009 | 169322 | 0.000 |
Why?
|
Aged, 80 and over | 1 | 2011 | 59683 | 0.000 |
Why?
|